Key Drivers
- Margin Strength
- Strong Cash Flow
- Rich Valuation
AIAI Summary
GRDN now looks like a volume-led operator whose real operating momentum—~10% resident/script growth, gross-margin expansion, and higher EBITDA guidance—is being offset by IRA-driven pricing pressure, so the key takeaway is that upside depends on converting unit growth into stronger free cash flow fast enough to justify a still-rich valuation and hold support near 35.0.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Strength
- •Strong Cash Flow
- •Rich Valuation
GRDN shows solid profitability and cash generation with improving gross margins and liquidity, but its high valuation, working-capital intensity, and sizable receivables/inventory temper the outlook.
Price Behavior
Key Price Behavior Insights:
- •Higher-low attempt
- •Range resistance
- •Support holding
Over the last month, GRDN was choppy and only slightly weaker, but the mid-May rebound suggests a possible short-term higher low, with $34.9-$35.0 support and $37.5-$37.9 resistance still defining the range.
Sharp mid-May drop followed by a three-session rebound
Sentiment & News
Key News Insights:
- •Earnings Beat
- •Higher EBITDA
- •Buy Ratings
Guardian Pharmacy delivered a solid Q1 earnings and revenue beat, raised adjusted EBITDA guidance, and maintained supportive analyst sentiment, signaling improving profitability momentum.
This update is likely positive for GRDN, as strong execution and improved profit outlook may support the stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings